ATTRibute CM TRIAL

What do you need to know in order to decide if participating in this study is right for you?

WHAT IS THE ATTRIBUTE-CM TRIAL?

ATTRibute-CM is a Phase 3 clinical study to evaluate an investigational medicine called AG10.

The trial will measure the effects of AG10 in participants with a misfolded transthyretin protein (ATTR-CM).

ATTR-CM occurs when the misfolded transthyretin protein has accumulated in the heart.



THE STUDY WILL MEASURE:

- Change in 6 minute walk distance
- All cause mortality and cardiovascular-related hospitalizations
- Long-term safety

WHO IS THIS STUDY FOR?

This study is for patients diagnosed with a misfolded transthyretin protein (ATTR-CM).



Eligible study participants will be between 18-90 years old and have been diagnosed with ATTR-CM with symptoms of heart failure. The study doctor will discuss other requirements to determine eligibility.

510 subjects with symptomatic ATTR-CM will be asked to participate in the study

340 subjects will receive AG10

170 subjects will receive placebo

If you qualify for this study, your doctor will discuss the risks and potential benefits of participating.

TIME COMMITMENT

The ATTRibute-CM Trial has three parts — screening, treatment, and optional follow-up.

Each person enrolled in the study will be making a 30 month (2.5 year) commitment, with an option to participate in an additional 30 month extension phase (2.5 years).

STUDY TIMELINE:

0 YEARS

35 DAYS:

SCREENING

Your doctor will check to see if you are able to participate

You will take several tests and provide blood and urine samples

30 MONTHS: (2.5 YEARS)



TREATMENT

You will be randomly assigned to one of two groups and receive either AG10 pills or placebo pills.

The doctor will perform several tests throughout this period, including walk distance ECGs to measure your heart rhythm, and measurements of your temperature, weight, blood pressure, urine, and blood samples to check how the study medicine acts in your body and if your heart function is improving.

30 MONTHS: (2.5 YEARS)

OPTIONAL FOLLOW-UP

As part of the follow up, you can opt to continue in the study for an additional 30 months (2.5 years). Your doctor will give you AG10 and continue to administer tests to measure your heart and body functions throughout the study.

5 YEARS

POSSIBLE BENEFITS

You may or may not receive any direct medical benefit from the study.

Your participation is part of the development program for AG10. If approved, this drug may provide another treatment option and help many people that have the same heart symptoms of ATTR-CM that you are living with.

RESPONSIBILITIES & COMPENSATION

As a subject in this study, you will have certain responsibilities:

- Provide consent to be a volunteer and understand all risk factors
- Complete questionnaires to assess your health and report on side effects
- Attend all study visits and participate in phone calls for check-ins
- Take AG10/placebo as instructed, notify your doctor of other medication use
- Avoid pregnancy or breastfeeding

- You will not have to pay for AG10 or any treatments or tests that are part of the study
- You may be reimbursed for travel expenses that are associated with study visits

PUBLIC SERVICE ANNOUNCEMENT

Your participation in this study is voluntary. Any personal information collected during the study will remain confidential.

HOW TO GET STARTED

If you are interested in learning more, talk to your doctor about this trial.

For more information and the list of participating clinical trial sites, visit ClinicalTrials.gov

https://clinicaltrials.gov/ct2/show/NCT03860935

eidos
a bridgebio company